pancreatic cancer vaccine
Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands
A rapid round-up of the top pharma, biotech and healthcare news
FDA OKs Valeant’s psoriasis drug Siliq, with black box warning
Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz
Valeant uncouples Dendreon and skincare brands to cut debt
Agrees deals worth $2.1bn with L’Oreal and Sanpower Group
Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’
Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands
Valeant’s ex-CEO and CFO ‘could face criminal charges’
Sources suggest probe may relate to the company’s former relationship with Philidor Rx Services
Allergan CEO takes issue with ‘predatory’ price increases
Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”
LEO Pharma picks up AZ skin disease drugs in $1bn deal
Gains rights to eczema and psoriasis treatments
NewLink pancreatic cancer vaccine flunks phase III test
Survival rate slightly lower for patients on vaccine than those in control group
Deal Watch March 2016
AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals
Valeant appoints Joseph Papa to end CEO uncertainty
He will take over from Michael Pearson at the troubled pharma company in May
Valeant begins search for new CEO
Michael Pearson will continue in the role until his successor is appointed